Glycation & AGEs Inhibition (Carnosine, Benfotiamine)

Navigation & Context

• Parent Hub: 04 - Longevity & Environment MOC
• Literature Dossier: Glycation & AGEs Inhibition (Carnosine, Benfotiamine) - References
• Related Nodes: Cellular Senescence & Senolytics (Fisetin, Quercetin, Dasatinib), Mitochondrial Biogenesis & Uncoupling

---

1. Geroscience & Biophysical Mechanism

Non-enzymatic glycation (the Maillard reaction in vivo) occurs when reducing sugars (glucose, fructose, ribose) or reactive dicarbonyl intermediates—principally methylglyoxal ($\text{MGO}$), glyoxal ($\text{GO}$), and 3-deoxyglucosone ($\text{3-DG}$)—react with free $ϵ$-amino groups of lysine and guanidino groups of arginine on long-lived structural proteins. Over weeks to years, reversible Schiff bases and Amadori products (such as ${\text{HbA}}_{1\text{c}}$) rearrange into irreversible Advanced Glycation End-products (AGEs) including carboxymethyllysine ($\text{CML}$), carboxyethyllysine ($\text{CEL}$), and pentosidine.

Pathophysiological Consequences of AGEs

1. Extracellular Matrix Cross-Linking: Long-lived proteins with multi-year half-lives—vascular collagen ($t_{1/2}\approx 15\text{ yrs}$), arterial elastin ($t_{1/2}\approx 40\text{–}70\text{ yrs}$), and ocular crystallins—develop covalent AGE cross-links. This stiffens the aorta (elevating systolic blood pressure and pulse pressure), impairs diastolic myocardial relaxation, causes skin elastosis, and opacifies the lens.
2. RAGE Receptor Activation: Circulating and dietary AGEs bind the transmembrane Receptor for Advanced Glycation End-products ($\text{RAGE}$) on endothelial cells, microglia, and podocytes, activating $\text{NADPH}$ oxidase ($\text{NOX}$) and sustained $\text{NF-}\kappa \text{B}$ nuclear translocation ($\text{IL-6},\text{VCAM-1},\text{TNF-}\alpha$).

Dual Biochemical Defense: Transketolase Shunting + Carbonyl Trapping

• Benfotiamine ($S$-benzoylthiamine $O$-monophosphate): A lipid-soluble prodrug of thiamine with 3.6- to 5-fold higher oral bioavailability and 120-fold greater intracellular thiamine diphosphate ($\text{TDP}$) penetration than water-soluble thiamine HCl. Benfotiamine allosterically activates transketolase ($\text{TKT}$) by 250–300%, shunting excess glycolytic fructose-6-phosphate and glyceraldehyde-3-phosphate ($\text{GA3P}$) into the non-oxidative pentose phosphate pathway. This starves the three major hyperglycemic damage pathways: $\text{MGO/AGE}$ formation, Protein Kinase C ($\text{PKC}$) activation, and the hexosamine pathway.
• L-Carnosine ($\beta$-alanyl-L-histidine): An endogenous dipeptide concentrated in skeletal muscle ($20\text{ mM}$) and brain olfactory/cortical tissue. Because its imidazole ring and $\beta$-amino group closely mimic target protein side chains, carnosine acts as a sacrificial carbonyl scavenger (“transglycating agent”), reacting directly with $\text{MGO}$, $\text{GO}$, and lipid-peroxidation aldehydes ($4\text{-HNE}$, malondialdehyde) to form harmless carnosine-aldehyde adducts excreted in urine.

---

2. Actionable Protocol & Dosing Architecture

Intervention	Dosage & Formulation	Timing	Mechanistic Role
Benfotiamine	$300\text{–}600\text{ mg/day}$ ($150\text{–}300\text{ mg}$ BID)	With largest carbohydrate-containing meals	Activates transketolase to prevent intracellular $\text{GA3P}\to \text{Methylglyoxal}$ overflow
L-Carnosine (or Sustained-Release $\beta$-Alanine)	$1,000\text{–}1,500\text{ mg/day}$ L-Carnosine (to overwhelm serum $\text{CN1}$ carnosinase) OR $3.2\text{ g/day}$ $\beta$-Alanine	Divided doses with meals	Direct dicarbonyl ($\text{MGO/4-HNE}$) trapping, ${\text{Cu}}^{2+}/{\text{Zn}}^{2+}$ chelation, and $\text{RAGE}$ inhibition
Pyridoxal-5’-Phosphate (P5P)	$25\text{–}50\text{ mg/day}$	AM with food	Coenzyme that traps Amadori intermediates before rearrangement into irreversible AGEs
Culinary Low-AGE Preparation	Poaching, steaming, sous-vide, slow-cooking ($<120^{\circ }\text{C}$), and acidic marinades (lemon/vinegar)	Every meal	Acidifying meat/protein with lemon juice or vinegar for 1 hour prior to cooking reduces exogenous dietary AGE ($\text{dAGE}$) formation by 50–60% compared to dry grilling/frying

---

3. Biomarkers & Quantification

• Glycemic Exposure & Glycated Proteins: ${\text{HbA}}_{1\text{c}}$ (optimal longevity target: $4.6\text{–}5.1\%$), Fructosamine / Glycated Albumin (reflects 2–3 week glycation stress, target $<13\%$), and Continuous Glucose Monitoring (CGM time-in-range $70\text{–}110\text{ mg/dL}>95\%$, postprandial peak $<120\text{ mg/dL}$).
• Direct AGE Assessment: Non-invasive Skin Autofluorescence (SAF) via AGE Reader (measures dermal pentosidine/cross-linked collagen fluorescence at $370\text{ nm}$ excitation / $440\text{ nm}$ emission) and serum $\text{CML}$ or soluble RAGE ($\text{sRAGE}$).

---

4. Key Scientific Evidence Summary

Full clinical citations and trial outcomes are documented in Glycation & AGEs Inhibition (Carnosine, Benfotiamine) - References:

• Stirban et al. (2006, Diabetes Care): In human subjects consuming a high-AGE meal, Benfotiamine ($1,050\text{ mg/day}$ for 3 days) completely prevented postprandial macrovascular and microvascular endothelial dysfunction (preserving flow-mediated dilation) and reduced serum $\text{CML}$ and methylglyoxal surges by 40–70% ($p<0.01$).
• Hammes et al. (2003, Nature Medicine): Demonstrated that benfotiamine activates transketolase by 250–300%, blocking three major biochemical pathways of hyperglycemic vascular damage (AGEs, $\text{PKC}$, hexosamine) and preventing experimental diabetic retinopathy.
• de Courten et al. (2016, Obesity) / Regazzoni et al. (2016): Human RCT of $2\text{ g/day}$ L-Carnosine for 12 weeks in overweight/obese adults prevented progression of insulin resistance, normalized 2-hour oral glucose tolerance glucose/insulin excursions, and increased urinary excretion of carnosine-acrolein/carbonyl adducts.
• Gibson et al. (2020, Journal of Alzheimer’s Disease): 12-month Phase IIa RCT of $600\text{ mg/day}$ Benfotiamine in mild cognitive impairment/early AD reduced clinical cognitive decline (ADAS-Cog) by 43% and significantly suppressed serum advanced glycation end-products ($p=0.044$).